Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features
Alessandra Fabi(Agostino Gemelli University Polyclinic), Marcella Mottolese, Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Giulio Metro(University of Perugia), C. Nisticò, Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), A. Di Benedetto, F. Cognetti(Sapienza University of Rome), Elisa Melucci
Cited by 2
Related Papers
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168